Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (V): wherein Ab represents an antibody. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P (I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: The present disclosure relates to compounds of formula (I): RCG1-L-P??(I) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

Abstract: Provided herein are compounds of formula (I):

Abstract: The invention relates to a method of analyzing spectral data for the selection of a calibration model, relating spectra of a substance to a physical or chemical parameter of the substance, over a predetermined range of the physical or chemical parameter, comprising the steps: a) capturing spectral data of the substance with respective values of the physical or chemical parameter over the predetermined range, b) creating a plurality of calibration models using the captured spectral data in dependence upon the values of the physical or chemical parameter based on the calibration data using statistical resampling methods, c) calculating tolerance intervals of the results at each reference level for each calibration model, and d) displaying the tolerance intervals at each reference level over the predetermined range for each calibration model.

Abstract: The invention relates to a method of analyzing spectral data for the selection of a calibration model, relating spectra of a substance to a physical or chemical parameter of the substance, over a predetermined range of the physical or chemical parameter, comprising the steps: a) capturing spectral data of the substance with respective values of the physical or chemical parameter over the predetermined range, b) creating a plurality of calibration models using the captured spectral data in dependence upon the values of the physical or chemical parameter based on the calibration data using statistical resampling methods, c) calculating tolerance intervals of the results at each reference level for each calibration model, and d) displaying the tolerance intervals at each reference level over the predetermined range for each calibration model.

Abstract: The invention relates to biotinylated low molecular weight heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use.

Abstract: The invention relates to biotinylated heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use. The biotinylated polysaccharides are of the formula (I) with the variables as defined herein.

Abstract: The present invention relates to the carboxyl-reduced derivatives of hyaluronic acid of formula (I): in which R or R1 represents H or SO3M, n is an integer of between 0 and 25 000, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: The present invention relates to the carboxyl-reduced and chemoselectively O-sulfated derivatives of chondroitin sulfate of formula (I): in which R1, R2, R3 and R4 are H or SO3M, n is an integer of between 0 and 200, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: The present invention relates to the carboxyl-reduced derivatives of dermatan sulfate of formula (I): in which R1, R2, R3 or R4 represents H or SO3M, n is an integer of between 0 and 150, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: Heterocyclylalkylpiperidine derivatives of general formula (I) in their enantiomeric or diastereoisomeric forms or mixtures of these forms, and/or, where appropriate, in their syn or anti form or a mixture thereof, as well as any salt thereof.

Abstract: Heterocyclylalkylpiperidine derivatives of general formula (I) 1

Abstract: Heterocyclylalkylpiperidine derivatives of general formula (I) in their enantiomeric or diastereoisomeric forms or mixtures of these forms, and/or, where appropriate, in their syn or anti form or a mixture thereof, as well as any salt thereof.

Abstract: Heterocyclylalkylpiperidine derivatives of general formula (I) 1

Abstract: The device includes a main receptacle (1) having an overflow pipe (2) and a secondary receptacle (9) mounted so as to be freely movable in the vertical direction inside the main receptacle (1). The inner space of the secondary receptacle (9) communicates with a drainage pipe (8) for fluid lost by the hydraulic installation. The secondary receptacle (9) floats in the fluid contained in the main receptacle (1). The immersion level of the secondary receptacle (9) increases, depending on the amount of lost fluid received by the secondary receptacle (9), and the supply of fluid from the main receptacle (1) is caused by the immersion of the secondary receptacle (9).

Abstract: A time accounting system for accounting for the time a process spends in a ready state, a wait state, or a running state. The system includes a time-of-day clock coupled to a central processing unit for outputting the time-of-day whenever a process changes state. A memory also coupled to the central processing unit stores the contents of a plurality of addressable process control blocks and each process control block includes first, second, and third storage locations for storing indications of the amount of time an associated process has been in the running, ready, and wait states, respectively. The central processor unit accesses the process control blocks and updates the process times stored therein in accordance with control signals generated by decoding a string of microinstructions stored in a control store memory. The time-of-day clock is accessed each time a process enters one of the running, ready, or wait states and each time the execution of a process is completed.

Abstract: A method of and apparatus for executing a family of instructions provides synchronization of processes in a multiprocessing system. Representations of processes awaiting data (information units) such as the completion of an asynchronous operation or the availability of a resource are stored in a memory in a first queue and representations of information units available to processes are stored in memory in a second queue. Transfer of information units between processes is controlled by data elements known as "semaphores" stored in the memory. Each semaphore contains a field having a numerical value identifying which of the two different kinds of queues is present.